Publications by authors named "Tim Delahaye"

Claim this Profile
S
Site-specific Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models.
Jonatan Dewulf, Tal Flieswasser, Tim Delahaye, Christel Vangestel, Alan Miranda

EJNMMI Radiopharm Chem· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model.
Clare I Campbell, Rhona McGonigal, Jennifer A Barrie, Jolien Delaere, Laura Bracke, Tim Delahaye

Brain Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Nicolas Leupin, Pier Luigi Zinzani, Franck Morschhauser, Stéphane Dalle, Marie Maerevoet, Tim Delahaye

Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma.
Astrid De Meulenaere, Tijl Vermassen, David Creytens, Stijn De Keukeleire, Tim Delahaye

Clin Transl Sci· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.
Carsten Riether, Thomas Pabst, Sabine Höpner, Ulrike Bacher, Magdalena Hinterbrandner, Tim Delahaye

Nat Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis